Evidence map›Paper›PMID 38129673›Full record

ArticleMolecular biotechnology2024

The m6A Reader YTHDC2 Suppresses Lung Adenocarcinoma Tumorigenesis by Destabilizing MRPL12.

Yingchuan Sun, Yanyan Liu, Pengyuan Wang, Lin Chang, Jianmin Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. The mCells · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Potential of Synbiotics and Probiotics as Chemopreventive Agent.Probiotics and antimicrobial proteins · 2024
    Review
  7. Review
  8. The Biological Role of LRPPRC in Human Cancers.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yingchuan SunDepartment of Oncology, Xuchang Central Hospital, No. 666, Wenxuan Street, Dongcheng District, Xuchang, 461000, China. 17703748953@163.com.ORCID http://orcid.org/0009-0004-6312-8367
Yanyan LiuThe Medical College of Xuchang University, Xuchang, 461000, China.
Pengyuan WangDepartment of Oncology, Xuchang Central Hospital, No. 666, Wenxuan Street, Dongcheng District, Xuchang, 461000, China.
Lin ChangThe Medical College of Xuchang University, Xuchang, 461000, China.
Jianmin HuangDepartment of Oncology, Xuchang Central Hospital, No. 666, Wenxuan Street, Dongcheng District, Xuchang, 461000, China.
Xuzhou Central Hospital · CNXuchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N6-methyladenosine (m6A) is the most common posttranscriptional RNA modification and plays significant roles in physiological and pathological progression. Here, we probed the functions and mechanism of the m6A reader YTH domain containing 2 (YTHDC2) in Lung Adenocarcinoma (LUAD) tumorigenesis. Levels of genes and proteins of YTHDC2 and Mitochondrial ribosomal protein L7/L12 (MRPL12) were assayed by quantitative real-time polymerase chain reaction, western blotting and Immunohistochemistry (IHC) analyses. In vitro analysis was conducted using 5-ethynyl-2'-deoxyuridine (EdU), colony formation, flow cytometry, and transwell assays, respectively. In vivo assay was performed by using the mouse lung adenocarcinoma model. The methylated RNA immunoprecipitation (MeRIP) assay was used to detect the m6A modification profile of MRPL12 mRNA. YTHDC2 was lowly expressed in lung adenocarcinoma tissues and cells. Overexpression of YTHDC2 suppressed the proliferation, invasion and migration of lung adenocarcinoma cells, but induced cell apoptosis. As expected, forced expression of YTHDC2 hindered lung adenocarcinoma tumor growth in vivo. Mechanistically, YTHDC2 preferentially bound to m6A-modified MRPL12 mRNA and destabilized its expression. MRPL12 was highly expressed in lung adenocarcinoma tissues and cells, and MRPL12 silencing repressed the growth and mobility of lung adenocarcinoma cells. Moreover, MRPL12 upregulation attenuated the anticancer activity of YTHDC2 in lung adenocarcinoma cells. In vivo assay also showed YTHDC2 suppressed tumor growth in the lung adenocarcinoma mouse model via downregulating MRPL12. The m6A reader YTHDC2 repressed lung adenocarcinoma tumorigenesis by destabilizing MRPL12 in an m6A-dependent manner.

Indexed as

Adenocarcinoma of LungAdenosineCell ProliferationGene Expression Regulation, NeoplasticLung NeoplasmsAnimalsApoptosisCarcinogenesisCell Line, TumorCell MovementHumansMiceMice, NudeMitochondrial ProteinsRibosomal ProteinsRNA-Binding ProteinsAdenosineMitochondrial ProteinsN-methyladenosineRibosomal ProteinsRNA-Binding ProteinsRNA HelicasesYTHDC2 protein, humanLung adenocarcinomam6A RNA methylationMRPL12YTHDC2

Identifiers

PMID38129673
OpenAlexW4390062584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.